Capivasertib - Latest Advances

A Case of Drug‒Induced Tubulointerstitial Nephritis Caused by Capivasertib Therapy

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: October 06, 2025

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

Journal: Journal of managed care & specialty pharmacy

Published: August 30, 2025

Kobochromone A, a polyphenol in Carex kobomugi, suppresses androgen signaling induced by 11-oxygenated androgens and enhances the efficacy of AKT inhibitors in triple-negative breast cancer cells.

Journal: Steroids

Published: July 28, 2025

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Journal: EClinicalMedicine

Published: July 15, 2025

Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: July 01, 2025

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.

Journal: BMC cancer

Published: June 17, 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 17, 2025

Dynamic changes of blood glucose level during capivasertib treatment in metastatic breast cancer: a case report.

Journal: Diabetology international

Published: June 13, 2025

Loss of CARM1 alters the developmental programming of Glioma stem-like cells and creates a druggable NGFR/NTRK dependency.

Journal: bioRxiv : the preprint server for biology

Published: May 05, 2025

Innovative dual-target AKT inhibitors unveiling novel mechanisms and translational potential.

Journal: Bioorganic chemistry

Published: April 22, 2025

Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer.

Journal: Computers in biology and medicine

Published: April 15, 2025

NICE recommends "targeted" drug capivasertib for advanced breast cancer.

Journal: BMJ (Clinical research ed.)

Published: April 14, 2025

Filters

A Case of Drug‒Induced Tubulointerstitial Nephritis Caused by Capivasertib Therapy

A Case of Drug‒Induced Tubulointerstitial Nephritis Caused by Capivasertib Therapy

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

Kobochromone A, a polyphenol in Carex kobomugi, suppresses androgen signaling induced by 11-oxygenated androgens and enhances the efficacy of AKT inhibitors in triple-negative breast cancer cells.

Kobochromone A, a polyphenol in Carex kobomugi, suppresses androgen signaling induced by 11-oxygenated androgens and enhances the efficacy of AKT inhibitors in triple-negative breast cancer cells.

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer.

Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer.

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review.

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review.

Dynamic changes of blood glucose level during capivasertib treatment in metastatic breast cancer: a case report.

Dynamic changes of blood glucose level during capivasertib treatment in metastatic breast cancer: a case report.

Loss of CARM1 alters the developmental programming of Glioma stem-like cells and creates a druggable NGFR/NTRK dependency.

Loss of CARM1 alters the developmental programming of Glioma stem-like cells and creates a druggable NGFR/NTRK dependency.

Innovative dual-target AKT inhibitors unveiling novel mechanisms and translational potential.

Innovative dual-target AKT inhibitors unveiling novel mechanisms and translational potential.

Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer.

Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer.

NICE recommends "targeted" drug capivasertib for advanced breast cancer.

NICE recommends "targeted" drug capivasertib for advanced breast cancer.